Cargando…

RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG

INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Petropoulos, James, Finkbeiner, Melanie, Assis, Zarina, Gallagher, Clare, Hader, Walter, Chan, Jennifer, Strother, Douglas, Lafay-Cousin, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164706/
http://dx.doi.org/10.1093/neuonc/noac079.044
_version_ 1784720199358873600
author Petropoulos, James
Finkbeiner, Melanie
Assis, Zarina
Gallagher, Clare
Hader, Walter
Chan, Jennifer
Strother, Douglas
Lafay-Cousin, Lucie
author_facet Petropoulos, James
Finkbeiner, Melanie
Assis, Zarina
Gallagher, Clare
Hader, Walter
Chan, Jennifer
Strother, Douglas
Lafay-Cousin, Lucie
author_sort Petropoulos, James
collection PubMed
description INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse prognostic factor. We present 2 cases of young children with recurrent metastatic DIA/DIG to describe their presentation, therapeutic management and outcome and to highlight the importance of molecular characterization of these rare tumors to guide adjuvant therapy. CASES DESCRIPTION: The first patient developed metastatic recurrence after initial gross total resection (GTR) of a localized DIG. The disseminated relapse was treated with monthly carboplatin and vincristine (CB/VCR). Complete response was achieved after 15 cycles and the patient has remained in continuous complete remission for 5 years. Post hoc molecular analysis of the tumor revealed a BRAF-RDX fusion. The second patient presented with a disseminated intraventricular relapse following an incomplete resection of a DIA associated with a SPECC1L-NTRK2 fusion. The patient received 2 cycles of CB/VCR with minimal response and was then switched to Larotrectinib leading to a very good partial response (VGPR) 3 months into therapy and has remained on treatment since then with significant clinical improvement. DISCUSSION/ CONCLUSION: In our 2 cases, metastatic recurrence was responsive to adjuvant therapy leading to complete response with conventional chemotherapy in the first one and to VGPR with NTRK inhibitor in the second patient. Early molecular characterization of these benign tumors is critical in case of incomplete resection or metastatic seeding to widen therapeutic options and maximize chance of cure. Response with NTRK inhibitor appears rapid and significant but the total duration of treatment and sustainability of response after discontinuation remain unknown.
format Online
Article
Text
id pubmed-9164706
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91647062022-06-05 RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG Petropoulos, James Finkbeiner, Melanie Assis, Zarina Gallagher, Clare Hader, Walter Chan, Jennifer Strother, Douglas Lafay-Cousin, Lucie Neuro Oncol Craniopharyngioma and Rare Tumors INTRODUCTION: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are glioneuronal tumors of early childhood. Surgical resection is usually sufficient to cure these benign tumors. The presence of metastatic seeding is rare and has been reported as an adverse prognostic factor. We present 2 cases of young children with recurrent metastatic DIA/DIG to describe their presentation, therapeutic management and outcome and to highlight the importance of molecular characterization of these rare tumors to guide adjuvant therapy. CASES DESCRIPTION: The first patient developed metastatic recurrence after initial gross total resection (GTR) of a localized DIG. The disseminated relapse was treated with monthly carboplatin and vincristine (CB/VCR). Complete response was achieved after 15 cycles and the patient has remained in continuous complete remission for 5 years. Post hoc molecular analysis of the tumor revealed a BRAF-RDX fusion. The second patient presented with a disseminated intraventricular relapse following an incomplete resection of a DIA associated with a SPECC1L-NTRK2 fusion. The patient received 2 cycles of CB/VCR with minimal response and was then switched to Larotrectinib leading to a very good partial response (VGPR) 3 months into therapy and has remained on treatment since then with significant clinical improvement. DISCUSSION/ CONCLUSION: In our 2 cases, metastatic recurrence was responsive to adjuvant therapy leading to complete response with conventional chemotherapy in the first one and to VGPR with NTRK inhibitor in the second patient. Early molecular characterization of these benign tumors is critical in case of incomplete resection or metastatic seeding to widen therapeutic options and maximize chance of cure. Response with NTRK inhibitor appears rapid and significant but the total duration of treatment and sustainability of response after discontinuation remain unknown. Oxford University Press 2022-06-03 /pmc/articles/PMC9164706/ http://dx.doi.org/10.1093/neuonc/noac079.044 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Craniopharyngioma and Rare Tumors
Petropoulos, James
Finkbeiner, Melanie
Assis, Zarina
Gallagher, Clare
Hader, Walter
Chan, Jennifer
Strother, Douglas
Lafay-Cousin, Lucie
RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title_full RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title_fullStr RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title_full_unstemmed RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title_short RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG
title_sort rare-19. molecular characterization and treatment response of metastatic dia/dig
topic Craniopharyngioma and Rare Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164706/
http://dx.doi.org/10.1093/neuonc/noac079.044
work_keys_str_mv AT petropoulosjames rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT finkbeinermelanie rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT assiszarina rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT gallagherclare rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT haderwalter rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT chanjennifer rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT strotherdouglas rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig
AT lafaycousinlucie rare19molecularcharacterizationandtreatmentresponseofmetastaticdiadig